Rakovina Therapeutics Presents Preclinical Data on its Novel kt-3000 Series at the 2022 AACR Special Conference on Sarcomas
May 11, 2022 09:00 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, May 11, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics Inc. Announces 2021 Financial Results and Provides Corporate Update
April 27, 2022 09:00 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, April 27, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics Presents Preclinical Data Supporting Potential Broad Anticancer Activity of kt-4000 Series at the American Association of Cancer Research (AACR) Annual General Meeting
April 12, 2022 09:00 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, April 12, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics to Present Abstract at the 2022 AACR Special Conference – Sarcomas
March 30, 2022 09:16 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, March 30, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics to Present Abstract at the 2022 Annual Meeting of the American Association of Cancer Research (AACR)
March 09, 2022 10:56 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, March 09, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics President to Join Expert Panel at the Fifth Annual DDR, ATR & PARP Inhibitors Summit
January 25, 2022 09:00 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV:RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based on...
Rakovina Therapeutics Inc. to Present at Biotech Showcase 2022
January 06, 2022 17:01 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV:RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based on...
Rakovina Therapeutics Announces Non-dilutive Financial Contributions to Support Lead Optimization of Novel Anti-cancer Agents
December 21, 2021 09:00 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics Inc. Announces Third Quarter 2021 Financial Results and Provides Corporate Update
November 23, 2021 17:25 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on...
Rakovina Therapeutics Partners with St. Baldrick’s Foundation to Research and Develop New Treatments for Childhood Bone Cancer
November 16, 2021 08:30 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based...